Alpha Cognition Inc. (7N70)
XFRA 
NASDAQ (CM) Primary XFRA Summary
7N70 Chart
Alpha Cognition Inc. (ACOG) Q1 2026 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) Q1 2026 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Tops Revenue Estimates
Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.2 per share a year ago.
Alpha Cognition Q1 Earnings Call Highlights
Alpha Cognition NASDAQ: ACOG reported 40% sequential revenue growth in the first quarter of 2026, as executives said commercial adoption of its Alzheimer's treatment ZUNVEYL continued to build across prescribers and long-term care facilities.
Alpha Cognition Inc. (7N70) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alpha Cognition Inc. ever had a stock split?
Alpha Cognition Inc. Profile
| Industrial Conglomerates Industry | Industrials Sector | Michael E. McFadden CEO | XFRA Exchange | CA02074J5017 ISIN |
| CA Country | 5 Employees | - Last Dividend | 5 Nov 2024 Last Split | - IPO Date |
Overview
Alpha Cognition Inc. is a clinical stage biopharmaceutical company that specializes in developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS), two debilitating neurodegenerative disorders. Founded in 2000 and originally named Crystal Bridge Enterprises Inc., the company underwent a name change to Alpha Cognition Inc. in March 2021. With its headquarters in Vancouver, Canada, Alpha Cognition Inc. is at the forefront of neurodegenerative disease research, focusing on creating innovative therapeutic solutions to improve the lives of patients affected by these conditions.
Products and Services
- ZUNVEYL (benzgalantamine)
- ALPHA-0602
- ALPHA-0702 and ALPHA-0802
This medication is targeted towards individuals suffering from mild-to-moderate Alzheimer's disease and mild traumatic brain injury. Through its action, ZUNVEYL aims to alleviate symptoms and enhance cognitive functions, thereby improving the quality of life for its users.
ALPHA-0602 represents Alpha Cognition Inc.'s venture into gene therapy, specifically designed for the treatment of ALS. This innovative approach seeks to slow down or halt the progression of ALS, offering hope for a more effective intervention for patients grappling with this challenging disease.
These are granulin epithelin motifs developed by Alpha Cognition Inc. for the treatment of neurodegenerative diseases. The compounds are under research for their potential to treat a wide range of neurodegenerative disorders by targeting the underlying mechanisms that contribute to cell death and disease progression.
